Abstract:Feng Yao, 1, &ast Chenguang Wang, 2, &ast Jie Ding, 1 Qian Zhang, 1 Liang Zheng, 1 Qin Zhang, 1 Tianshu Yang, 2 Xunmin Zhang, 2 Yong Shan, 2 Sheng Hou, 2 Hao Wang, 2 Renpeng Zhou, 1 Wei Hu 1 1 Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China; 2 Taizhou Mabtech Pharmaceutical Co., Ltd, Taizhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Hu; Renpeng Zhou, Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, Anhui, 230601, People's Republic of China, Tel/Fax + 86 0551 65997164, Email ; Purpose: Secukinumab, a monoclonal antibody targeting interleukin (IL)-17A, is approved for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. This study compared the pharmacokinetics (PK), safety, and immunogenicity of CMAB015, a candidate secukinumab biosimilar, with the reference product secukinumab (Cosentyx ® ) in healthy Chinese male subjects. Patients and methods: This double-blind, parallel-group study randomized healthy Chinese male subjects (N=130) to receive either a single dose of 150 mg CMAB015 or secukinumab subcutaneously. Primary study endpoints were PK parameters such as the maximum concentration (C max ) and area under the curve from zero to infinity (AUC 0-inf ), while safety and immunogenicity were secondary endpoints. Results: The 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of C max and AUC 0-inf for CMAB015 to secukinumab were all within the bioequivalence limits (80.00– 125.00%). Other PK parameters were comparable between the groups. The safety profile of CMAB015 was similar to that of secukinumab, with no serious adverse events related to treatment. The incidence of TEAEs was slightly higher in the CMAB015 group, but these events were mild to moderate in severity and did not lead to any withdrawals from the study. Immunogenicity analysis revealed low rates of anti-drug antibody (ADA) positivity, with similar rates between CMAB015 and secukinumab. Conclusion: This study demonstrated equivalent PK, comparable safety, and immunogenicity of CMAB015 to secukinumab in healthy Chinese male subjects. These findings support further clinical evaluation of CMAB015 as a secukinumab biosimilar. Trial Registration: The trial was registered on Clinicaltrials.gov (Identifier No. NCT05734482) and Chinadrugtrials.org.cn (Identifier No. CTR20230105). Keywords: CMAB015, secukinumab, biosimilar, pharmacokinetics, safety, immunogenicity Interleukin-17A (IL-17A) is a pro-inflammatory cytokine belonging to the IL-17 family, known for its pivotal role in orchestrating inflammatory and immune responses. 1,2 Developed by Novartis, secukinumab is a fully human monoclonal antibody that specifically targets and neutralizes IL-17A, thereby interrupting the inflammatory cascade driven by this cytokine. 3 The efficacy and safety of secukinumab have been well established in clinical trials, leading to its approval for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. 4–8 In particular, Phase III clinical trials have demonstrated the effectiveness of secukinumab in Chinese patients with moderate to severe plaque psoriasis, highlighting its potential as a valuable treatment option in this population. 9 Since its initial approval in Japan in December 2014, secukinumab has received regulatory approval in numerous countries, including the United States and the European Union, underscoring its global significance in the management of IL-17A-driven diseases. 10 The emergence of biosimilars offers a promising avenue for expanding access to effective biologic therapies while addressing cost considerations. A biosimilar is a biological product that is highly similar to an approved originator or reference product, with no clinically meaningful differences in safety, purity, or potency. 11 Biosimilars have the potential to increase treatment options for patients and healthcare providers, offering a more affordable alternative to costly biologic therapies. 12 The development and approval of biosimilars follow a well-regulated process in many countries. The European Medi -Abstract Truncated-

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab among Chinese Healthy Subjects.

Biosimilarity of HS-20090 to Denosumab in Healthy Chinese Subjects: a Randomized, Double-Blinded, Pharmacokinetics/pharmacodynamics Study

A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‐P41 and reference denosumab in healthy males

Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study.

Phase 1 Studies Comparing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HLX01（a Rituximab Biosimilar） to Reference Rituximab in Chinese Patients with CD20-positive B-cell Lymphoma

Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study

MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects

A multicenter, randomized, double-blind, phase III trial comparing denosumab biosimilar QL1206 and denosumab in patients with bone metastases from solid tumors.

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

Comparison of the Efficacy and Safety of the Adalimumab Biosimilar TQ-Z2301 and Adalimumab for the Treatment of Chinese Patients with Active Ankylosing Spondylitis: a Multi-Center, Randomized, Double-Blind, Phase III Clinical Trial

Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males

A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects

Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared with Denosumab for Solid Tumor–Related Bone Metastases

A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)

FRI0422 HS016, A PROPOSED ADALIMUMAB BIOSIMILAR, SHOWED EQUIVALENT PHARMACOKINETICS AND SIMILAR SAFETY, IMMUNOGENICITY AND TOLERABILITY TO CHINA-LICENSED ADALIMUMAB IN HEALTHY MALE SUBJECTS, ACCORDING TO A 2.3-MONTHS PHASE I STUDY

A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers

A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar

A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults

A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men